Christopher Williamson
About Christopher Williamson
Christopher Williamson is a Principal Scientist at AbCellera, with extensive experience in translational science and pharmaceutical pharmacology. He holds a PhD in Biochemistry & Molecular Biology from the University of Calgary and has worked in various research roles across notable organizations in Canada and the UK.
Current Role at AbCellera
Christopher Williamson serves as a Principal Scientist at AbCellera, a position he has held since 2022. In this role, he continues to contribute to the company's research initiatives, focusing on the development of therapeutic agents. His work is centered on identifying patient-selective and pharmacodynamic biomarkers that enhance personalized treatment approaches.
Previous Experience at AbCellera
Before his current role, Christopher Williamson worked at AbCellera as a Senior Research Scientist from 2019 to 2022. During this time, he was involved in various research projects aimed at advancing pre-clinical development in the field of oncology and pain management. His contributions helped shape the direction of the company's scientific endeavors.
Professional Background in Pharmaceutical Research
Christopher Williamson has extensive experience in the pharmaceutical industry, having worked at several organizations. He was a Senior Research Scientist at Phoenix Molecular Designs for eight months in 2017 and served as a Scientist in Translational Biology at Aquinox Pharmaceuticals, Inc. from 2017 to 2018. His career reflects a strong focus on translational science and pharmacology.
Education and Academic Qualifications
Christopher Williamson earned a Bachelor of Science (BSc) in Biochemistry and a Doctor of Philosophy (PhD) in Biochemistry & Molecular Biology from the University of Calgary. His academic background laid the foundation for his expertise in pharmaceutical pharmacology, cellular and molecular biology techniques, and large data set analysis.
Post-Doctoral Research Experience
Christopher Williamson completed his post-doctoral fellowship at Cancer Research UK from 2011 to 2013, followed by an Industrial Post-Doctoral Fellowship at The Institute of Cancer Research from 2013 to 2016. His research focused on discovering novel patient-selective biomarkers for ATR inhibitors, contributing to advancements in cancer treatment.